Arcturus Therapeutics Holdings reported a GAAP loss of $51.169 million for the 3 months of 2022, down 9.2% from $56.346 million in the prior year. Revenue increased 2.5 times to $5.244 million from $2.127 million a year earlier.
Arcturus Therapeutics Holdings reported a GAAP loss of $51.169 million for the 3 months of 2022, down 9.2% from $56.346 million in the prior year. Revenue increased 2.5 times to $5.244 million from $2.127 million a year earlier. 
ir.arcturusrx.com
English (US) 